Biomarin Pharmaceutical (BMRN) Tax Provisions (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Tax Provisions came in at $35.7 million in Q1 2026, down 31.92% YoY from $52.4 million in Q1 2025, and up 83.71% on a QoQ basis from $19.4 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Tax Provisions (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Tax Provisions data on file, last reported at $35.7 million in Q1 2026.
- Quarterly Tax Provisions fell 31.92% year-over-year to $35.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.9 million (down 22.32% YoY) and the FY2025 annual result came in at $133.6 million, up 16.25% from the prior year.
- Tax Provisions improved to $35.7 million in Q1 2026, from $19.4 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $57.3 million in Q2 2025 to a low of -$17.3 million in Q4 2022.
- A 5-year average of $18.4 million and a median of $14.8 million in 2023 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2022 — Tax Provisions tumbled 99.5% — and 2024, when it soared 4364.89%.
- Tracing BMRN's Tax Provisions over 5 years: stood at -$17.3 million in 2022, then surged by 93.95% to -$1.0 million in 2023, then soared by 4364.89% to $44.7 million in 2024, then tumbled by 56.55% to $19.4 million in 2025, then soared by 83.71% to $35.7 million in 2026.
- The last three Tax Provisions figures came in at $35.7 million (Q1 2026), $19.4 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 16.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.62 Mn |
| Mar 31, 2026 | 35.68 Mn |
| Dec 31, 2025 | 19.42 Mn |
| Sep 30, 2025 | 4.42 Mn |
| Jun 30, 2025 | 57.34 Mn |
| Mar 31, 2025 | 52.40 Mn |
| Dec 31, 2024 | 44.70 Mn |
| Sep 30, 2024 | 28.36 Mn |
| Jun 30, 2024 | 24.96 Mn |
| Mar 31, 2024 | 16.89 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Sep 30, 2023 | 1.29 Mn |
| Jun 30, 2023 | 14.77 Mn |
| Mar 31, 2023 | 5.91 Mn |
| Dec 31, 2022 | -17.31 Mn |
| Sep 30, 2022 | 4.75 Mn |
| Jun 30, 2022 | 7.19 Mn |
| Mar 31, 2022 | 13.39 Mn |
| Dec 31, 2021 | -8.68 Mn |
| Sep 30, 2021 | -9.67 Mn |